Gan & Lee Pharmaceuticals. reported earnings results for the half year ended June 30, 2025. For the half year, the company reported sales was CNY 2,066.8 million compared to CNY 1,311.48 million a year ago.
Sales was CNY 2,066.8 million compared to CNY 1,314.89 million a year ago. Sales was CNY 2,062.48 million compared to CNY 1,311.48 million a year ago. Sales was CNY 2,062.48 million compared to CNY 1,314.89 million a year ago.
Revenue was CNY 2,066.8 million compared to CNY 1,314.89 million a year ago. Net income was CNY 603.68 million compared to CNY 298.9 million a year ago. Net income was CNY 603.68 million compared to CNY 298.9 million a year ago.
Net income was CNY 603.68 million compared to CNY 298.9 million a year ago. Net income was CNY 603.68 million compared to CNY 298.9 million a year ago. Basic earnings per share from continuing operations was CNY 1.02 compared to CNY 0.51 a year ago.
Basic earnings per share from continuing operations was CNY 1.02 compared to CNY 0.51 a year ago. Basic earnings per share from continuing operations was CNY 1.02 compared to CNY 0.51 a year ago. Basic earnings per share from continuing operations was CNY 1.02 compared to CNY 0.51 a year ago.
Diluted earnings per share from continuing operations was CNY 1.02 compared to CNY 0.51 a year ago. Diluted earnings per share from continuing operations was CNY 1.02 compared to CNY 0.51 a year ago. Diluted earnings per share from continuing operations was CNY 1.02 compared to CNY 0.51 a year ago.
Diluted earnings per share from continuing operations was CNY 1.02 compared to CNY 0.51 a year ago.
